Feds Award $three Million In Grants To Study Marijuana Components As Options To Opioids


The federal government has awarded $three million in grants for analysis into the therapeutic added benefits of components in marijuana other than THC, emphasizing their possible as options to prescription opioids.

In a notice published on Thursday, the National Institutes of Well being (NIH) explained why the research have been needed and listed grant recipients and the subjects they will investigate. That contains analysis into the use of CBD for arthritis discomfort, which will be led by New York University College of Medicine.

“The remedy of chronic discomfort has relied heavily on opioids, in spite of their possible for addiction and overdose and the reality that they generally do not operate effectively when utilized on a extended-term basis,” Helene Langevin, director of the National Center for Complementary and Integrative Well being (NCCIH), mentioned in a press release. “There’s an urgent have to have for far more successful and safer choices.”

A total of nine grants have been issued, with NIH stating that the funds will assist determine option remedy choices for discomfort and give info about the influence of consuming cannabis compounds such as CBD and other lesser-recognized cannabinoids as effectively as terpenes discovered in the plant.

“The cannabis plant consists of far more than 110 cannabinoids and 120 terpenes, but the only compound that is been studied extensively is THC,” the press release mentioned.

But when THC is recognized to treat specific types of discomfort, NIH is concerned that its intoxicating effects limit its healthcare applicability.

“THC may well assist relieve discomfort, but its worth as an analgesic is restricted by its psychoactive effects and abuse possible,” David Shurtleff, deputy director of NCCIH, mentioned. “These new projects will investigate substances from cannabis that do not have THC’s disadvantages, hunting at their simple biological activity and their possible mechanisms of action as discomfort relievers.”

NIH initially announced that it would be issuing grants for research into minor cannabinoids and terpenes final year.

Federal wellness agencies are not the only institutions interested in studying about marijuana compounds other than THC. On Wednesday, a Senate committee issued a spending report that known as for analysis into CBD and CBG when also criticizing the federal drug scheduling method for inhibiting such analysis.

Study descriptions of the federal cannabinoid and terpene analysis grant awards beneath:

Mechanism and Optimization of CBD-Mediated Analgesic Effects Boston Children’s Hospital, Boston, Zhigang He, Ph.D., B.M., and Juan Hong Wang, Ph.D. This project will investigate how the discomfort-relieving effects of cannabidiol (CBD) and other minor cannabinoids may well be modulated by the activity of potassium-chloride cotransporter two (KCC2), a chloride extruder expressed in most neurons. (Grant 1R01AT010779)

Neuroimmune Mechanisms of Minor Cannabinoids in Inflammatory and Neuropathic Discomfort University of California, San Francisco Judith Hellman, M.D., and Mark A. Schumacher, M.D., Ph.D. This project will discover the effects of minor cannabinoids on inflammatory and neuropathic discomfort in vitro and in vivo, focusing on the interactions of the cannabinoids with the peripheral receptor known as TRPV1 and a cannabinoid receptor, CB1R. (Grant 1R01AT010757)

Minor Cannabinoids and Terpenes: Preclinical Evaluation as Analgesics Investigation Triangle Institute, Investigation Triangle Park, North Carolina Jenny L. Wiley, Ph.D. This project will evaluate purified biosynthesized minor cannabinoids and chosen terpenes alone and in planned combinations to establish their possible efficacy as discomfort relievers against acute thermal, inflammatory, neuropathic, and visceral discomfort. (Grant 1R01AT010773)

Identifying the Mechanisms of Action for CBD on Chronic Arthritis Discomfort New York University College of Medicine, New York City Yu-Shin Ding, Ph.D. This project will use neuroimaging research and behavioral assessments to investigate the mechanisms of action of CBD in the modulation of chronic discomfort related with osteoarthritis in a mouse model. (Grant 1R21AT010771)

Synthetic Biology for the Chemogenetic Manipulation of Discomfort Pathways University of Texas, Austin Andrew Ellington, Ph.D. This project will use a novel technique to evolve person variants of cannabinoid receptor sort two (CB2) that interact with higher affinity with minor cannabinoids and evaluate the new variants in a mouse model of discomfort. (Grant 1R21AT010777)

Exploring the Mechanisms Underlying the Analgesic Impact of Cannabidiol Working with Proton Magnetic Resonance Spectroscopy University of Utah, Salt Lake City Deborah A. Yurgelun-Todd, Ph.D. This project will use proton magnetic resonance spectroscopy (1H-MRS) to evaluate modifications in brain chemistry in vital discomfort-processing regions immediately after brief-term administration of a cannabis extract enriched in CBD. (Grant 1R21AT010736)

Mechanistic Research of Analgesic Effects of Terpene Enriched Extracts from Hops Emory University, Atlanta Cassandra L. Quave, Ph.D. This project will take a multidisciplinary method to investigate the analgesic effects of terpenes from Humulus lupulus (hops), a plant that is closely connected to cannabis and has a extremely equivalent terpene profile. (Grant 1R21AT010774)

Systematic Investigation of Uncommon Cannabinoids With Discomfort Receptors University of Illinois at Urbana-Champaign David Sarlah, Ph.D. This project entails synthesizing a number of classes of uncommon phytocannabinoids, systematically evaluating their anti-inflammatory possible, and examining the effects of the compounds with the strongest anti-inflammatory possible on the key receptors involved in discomfort sensation. (Grant 1R21AT010761)

Analgesic efficacy of single and combined minor cannabinoids and terpenes Temple University, Philadelphia Sara J. Ward, Ph.D. This project will use rodent models of discomfort to evaluate the effects of 4 biologically active elements of cannabis that may well act synergistically to shield against discomfort improvement and to assess the interactions of these 4 substances with morphine. (Grant 1R01AT010778)

Senate Report Slams Drug Scheduling Method For Blocking Marijuana Investigation


Marijuana Moment is created doable with help from readers. If you rely on our cannabis advocacy journalism to keep informed, please contemplate a month-to-month Patreon pledge.


Latest posts